Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab

The bispecific T cell engager blinatumomab has shown encouraging clinical activity in B-precursor acute lymphoblastic leukemia (ALL). However, about half of relapsed/refractory patients do not respond to therapy. Here, we present the case of a 32-year-old male patient with refractory B-precursor ALL...

Descripción completa

Detalles Bibliográficos
Autores principales: Köhnke, Thomas, Krupka, Christina, Tischer, Johanna, Knösel, Thomas, Subklewe, Marion
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599591/
https://www.ncbi.nlm.nih.gov/pubmed/26449653
http://dx.doi.org/10.1186/s13045-015-0213-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599591/
https://www.ncbi.nlm.nih.gov/pubmed/26449653
http://dx.doi.org/10.1186/s13045-015-0213-6

Ejemplares similares